BioCentury
ARTICLE | Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

December 15, 2020 2:36 AM UTC

Vida leads Locanabio’s $100M B round
Locanabio Inc. raised $100 million in a series B financing led by Vida Ventures, with participation from new investors RA Capital, Invus, Acuta Capital and SVB Leerink as well as existing investors Arch Venture Partners, Temasek, Lightstone Ventures, UCB Ventures and GV. The genetic repeat expansion diseases company will use the funds to advance its RNA-targeted gene therapies into IND-enabling studies and expand its technology platform. Vida director Rajul Jain joined Locanabio’s board. 

Hemab launches to develop bispecific mAbs for rare bleeding disorders
Novo Seeds is funding Hemab ApS, which emerged with an exclusive license from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) to IP to develop a therapy for hemophilia and other rare bleeding disorders as well as an exclusive license to the bispecific DuoBody platform from  Genmab A/S (CSE:GMAB; NASDAQ:GMAB). Novo Seeds partner Jørgen Petersen was appointed Hemab’s chairman; Camilla Hansen, Novo Seeds senior associate, and Benny Sørensen, SVP, head of clinical development at Codiak BioSciences Inc. (NASDAQ:CDAK), will also join the board...